Clopidogrel/Acetylsalicylic acid Teva

RSS

clopidogrel / acetylsalicylic acid

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Clopidogrel/Acetylsalicylic acid Teva has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 28/04/2017

Authorisation details

Product details
Name
Clopidogrel/Acetylsalicylic acid Teva
Agency product number
EMEA/H/C/002272
Active substance
  • clopidogrel
  • acetylsalicylic acid
International non-proprietary name (INN) or common name
clopidogrel / acetylsalicylic acid
Therapeutic area (MeSH)
  • Acute Coronary Syndrome
  • Myocardial Infarction
Anatomical therapeutic chemical (ATC) code
B01AC30
Publication details
Marketing-authorisation holder
Teva Pharma B.V.
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
01/09/2014
Contact address
Swensweg 5
2031GA Haarlem
The Netherlands

Product information

03/06/2016 Clopidogrel/Acetylsalicylic acid Teva - EMEA/H/C/002272 - IA/0002

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

combinations

Therapeutic indication

Clopidogrel/Acetylsalicylic acid Teva is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). Clopidogrel/Acetylsalicylic acid Teva is a fixed‑dose combination medicinal product for continuation of therapy in:

  • Non‑ST segment elevation acute coronary syndrome (unstable angina or non‑Q‑wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention

ST segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy

Assessment history

How useful was this page?

Add your rating